» Articles » PMID: 30283753

Methods of Blood Pressure Assessment Used in Milestone Hypertension Trials

Overview
Journal Pulse (Basel)
Date 2018 Oct 5
PMID 30283753
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

In the present review, we summarized the blood pressure (BP) measurement protocols of contemporary outcome trials in hypertension. In all these trials, clinic BP was used for the diagnosis and therapeutic monitoring of hypertension. In most trials, BP was measured in the sitting position with mercury sphygmomanometers or automated electronic BP monitors by trained observers. BP readings were taken on each occasion at least twice with a 30-to-60-s interval after 5 min of rest. Details regarding the arm side, cuff size, and the timing of BP measurement were infrequently reported. If clinic BP continues being used in future hypertension trials, the measurement should strictly follow current guidelines. The observers must be trained and experienced, and the device should be validated by automated electronic BP monitors. On each occasion, BP readings should be taken 2-3 times. The time interval between successive measurements has to be 30-60 s, and the resting period before the measurement should be at least 5 min in the supine or seated position and 1-3 min standing. BP should usually be measured in the seated position. The higher arm side and an appropriate size cuff should be chosen and noted. BP should be measured at defined trough hours. Automated office BP measurement has recently been used and seems to have less white-coat effect. The out-of-office BP measurement, either ambulatory or home BP monitoring, was only used in a subset of study participants of few hypertension trials. Future trials should consider these novel office or out-of-office BP measurements in guiding the therapy and preventing cardiovascular events.

Citing Articles

Increased serum ATG5 as a marker of autophagy in psoriasis vulgaris patients: a cross-sectional study.

Abu El-Hamd M, Abdel-Hamid S, Hamdy A, Abdelhamed A Arch Dermatol Res. 2024; 316(8):491.

PMID: 39066827 DOI: 10.1007/s00403-024-03219-2.


First, a seat; then, an upgrade.

Sathyanarayanan A J Hum Hypertens. 2024; 38(8):620-623.

PMID: 38987380 DOI: 10.1038/s41371-024-00933-2.


Study protocol for family model diabetes self-management education with Marshallese participants in faith-based organizations.

McElfish P, Riklon S, Purvis R, Long C, Felix H, Hudson J Contemp Clin Trials Commun. 2022; 30:101007.

PMID: 36186543 PMC: 9515595. DOI: 10.1016/j.conctc.2022.101007.


Perceptions of pharmacists on the quality of automated blood pressure devices: a national survey.

Picone D, Peterson G, Jackson S, Campbell N, Delles C, Olsen M J Hum Hypertens. 2022; 37(3):235-240.

PMID: 35314763 PMC: 9995266. DOI: 10.1038/s41371-022-00670-4.


Prevalence of hypertension and its associated factors in Hawassa city administration, Southern Ethiopia: Community based cross-sectional study.

Paulose T, Nkosi Z, Endriyas M PLoS One. 2022; 17(3):e0264679.

PMID: 35231073 PMC: 8887727. DOI: 10.1371/journal.pone.0264679.


References
1.
Stergiou G, Kollias A, Destounis A, Tzamouranis D . Automated blood pressure measurement in atrial fibrillation: a systematic review and meta-analysis. J Hypertens. 2012; 30(11):2074-82. DOI: 10.1097/HJH.0b013e32835850d7. View

2.
Staessen J, Fagard R, Thijs L, Celis H, Arabidze G, Birkenhager W . Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997; 350(9080):757-64. DOI: 10.1016/s0140-6736(97)05381-6. View

3.
Kasanuki H, Hagiwara N, Hosoda S, Sumiyoshi T, Honda T, Haze K . Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for.... Eur Heart J. 2009; 30(10):1203-12. DOI: 10.1093/eurheartj/ehp101. View

4.
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G . Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342(3):145-53. DOI: 10.1056/NEJM200001203420301. View

5.
Wang J, Liu G, Wang X, Zhang S, Sun M, Pan X . Long-term blood pressure control in older Chinese patients with isolated systolic hypertension: a progress report on the Syst-China trial. J Hum Hypertens. 1996; 10(11):735-42. View